AbbVie Inc. reported significant financial performance for the second quarter of 2026, with net revenues reaching $16.99 billion, a 10.2% increase from $15.42 billion in the same period of 2025. For the first half of 2026, the company generated $31.99 billion in net revenues, up 11% from $28.77 billion year-over-year. Operating earnings for the second quarter were $6.43 billion, compared to $4.89 billion in the prior year, while net earnings attributable to AbbVie Inc. surged to $3.61 billion, up from $941 million in the same quarter of 2025. The diluted earnings per share also rose to $2.03, compared to $0.52 a year earlier.
The company experienced notable changes in its product portfolio, particularly in its immunology segment. Revenues from Skyrizi increased by 24% to $5.51 billion for the second quarter, driven by strong market share uptake. Similarly, Rinvoq's revenues rose by 24% to $2.53 billion. However, Humira, which has faced increased competition from biosimilars, saw a significant decline in revenues, dropping 36% to $756 million. This shift reflects the ongoing impact of market dynamics following the loss of exclusivity for Humira.
Strategically, AbbVie announced its intention to acquire Apogee Therapeutics, a clinical-stage biotechnology company, for approximately $10.9 billion. This acquisition is expected to enhance AbbVie's capabilities in treating inflammatory conditions. Additionally, AbbVie has been expanding its manufacturing capabilities, including a new pharmaceutical manufacturing campus in North Carolina and two new facilities in Illinois, aimed at supporting its growing pipeline in immunology, neuroscience, and oncology.
Operationally, AbbVie reported a cash flow from operations of $7.27 billion for the first half of 2026, an increase from $6.79 billion in the same period of 2025. The company’s total assets grew to $135.12 billion, up from $133.96 billion at the end of 2025. AbbVie’s employee headcount remained stable, with 1,767 million shares of common stock outstanding as of June 30, 2026. The company continues to focus on its research and development pipeline, which includes approximately 90 compounds in various stages of development, with expectations for multiple regulatory submissions and approvals in the coming year.
Looking ahead, AbbVie aims to leverage its diversified revenue base and strong commercial execution to drive growth. The company anticipates continued investment in its pipeline and on-market products, while also navigating the regulatory landscape shaped by recent agreements with the U.S. government regarding pricing and access to its products. AbbVie remains committed to maintaining a strong financial position, with plans to return cash to shareholders through dividends and share repurchases, while also investing in innovation and growth opportunities.
About AbbVie Inc.
AbbVie Inc. is a global biopharmaceutical company focused on researching, developing, manufacturing, and marketing innovative therapies across immunology, oncology, aesthetics, neuroscience, and eye care. Its diverse product portfolio addresses complex diseases with leading biologics and pharmaceuticals, serving healthcare providers, payers, and patients worldwide. AbbVie’s integrated business model combines advanced R&D, global supply chain, and targeted commercialization to deliver specialized medicines and medical devices in major international markets.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.
View the complete official filing on the SEC website.
Read on SEC.gov